- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01890889
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health (AdBiotech)
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health
Aperçu de l'étude
Statut
Les conditions
Description détaillée
To evaluate the safety and efficacy of a food-source nutrient by comparing changes in total cholesterol levels, 44 other blood chemistries, and self-reported quality of life as a function of consuming two different functional-food supplements versus a placebo in a 60-day study.
Upon completion of the pre-study screening, and after having received an explanation of the requirements, risks and benefits, and completing the informed consent interview with the research coordinator, subjects will execute a written informed consent. Subjects will be randomly assigned to one of three study groups.
Relevant Background Information.
A factor leading to development of vascular disease, a leading cause of death in industrialized nations, is elevated serum cholesterol. It is estimated that 19% of Americans between the ages of 20 and 74 years of age have high serum cholesterol. However, in an analysis of 10,000 test results in our database from subjects similar to those who are likely to participate in this study, we found 37% of subjects had TC scores between 200 and 250 and 10.3% above 250.
The most prevalent form of vascular disease is arteriosclerosis, a condition associated with the thickening and hardening of the arterial wall. The regulation of whole-body cholesterol homeostasis involves the regulation of intestinal cholesterol absorption, cellular cholesterol trafficking, a modulation of cholesterol biosynthesis, bile acid biosynthesis, steroid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. Regulation of intestinal cholesterol absorption has proven to be an effective means by which to regulate serum cholesterol levels.
Ad-Chol-Pre (ACP) is a functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe. In previous unpublished pilot studies examining the safety and efficacy of ACP include:
- ACP was shown to produce a statistically inhibition of [3H]-Cholesterol absorption from 50 ug/ml (P<0.05) in NPC1L1 over-expressing HepG2 cell lines as compared to an inhibition of 10ug/ml with Ezetimibe alone.
- I preliminary unpublished animal studies, ACP was shown to significantly inhibit radiolabelled cholesterol. ACP was found to significantly lower total cholesterol (38% ~56%) and LDL cholesterol (46~57%) in bloods from animals fed who had been fed a high fat diet for 6 weeks.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Patricia L Keith
- Numéro de téléphone: 210-824-4200
- E-mail: hmrcenterstudy@gmail.com
Lieux d'étude
-
-
Texas
-
San Antonio, Texas, États-Unis, 78209
- Recrutement
- Integrative Health Technologies
-
Contact:
- Patricia l Keith, BBA
- Numéro de téléphone: 210-824-4200
- E-mail: hmrcenterstudy@gmail.com
-
Sous-enquêteur:
- Patricia L Keith, BBA
-
Sous-enquêteur:
- Samuel C Keith, BBA
-
Sous-enquêteur:
- Joel A Michalek, PhD
-
Sous-enquêteur:
- Harry A Croft, MD
-
Contact:
- Mike E Gale, BS
- Numéro de téléphone: 210-824-4200
- E-mail: hmrcenterstudy@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- be an English-speaking male or female at least 18 years of age;
- have a total cholesterol level between 200 mg/dL and 250mg/dL
- have a LDL level between 100 mg/dL and 160 mg/dL
- not have allergic reactions to eggs or egg products
- not have consumed cholesterol-lowering drugs within 2 months of starting the study
- agree to follow the requirements of the study as set forth in this Informed Consent
- agree to withdraw from the study if becoming pregnant during the study.
Exclusion Criteria:
- do not speak English;
- are under 18 years of age;
- have a total cholesterol level below 200 mg/dL or above 250 mg/dL
- have a LDL level below 100 mg/dL or above 160 mg/dL
- have allergic reactions to eggs or egg products
- have consumed cholesterol-lowering drugs within 2 months of starting the study
- are pregnant or nursing;
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Ad-Chol-Pre
A functional food ingredient designed to inhibit cholesterol absorption.
ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY.
NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
|
Autres noms:
|
Comparateur actif: Half-dose Ad-Chol-Pre
A half-dose of the active comparator in arm one is administered.
A functional food ingredient designed to inhibit cholesterol absorption.
ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY.
NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
|
Autres noms:
|
Comparateur placebo: Capsule containing inactive component of defatted egg yolk
Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
|
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Change from baseline in Total Cholesterol and LDL levels at 30 days
Délai: 0 and 30 days
|
0 and 30 days
|
Change from baseline in Total Cholesterol and LDL levels at 60 days
Délai: 0 and 60 days
|
0 and 60 days
|
Change from mid-point in Total Cholesterol and LDL levels at 60 days
Délai: 30 and 60 days
|
30 and 60 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Blood Chemistry Measurements
Délai: 0, 30, and 60 days
|
Remaining lipids, Complete Blood Count, Metabolic Panel, Thyroid Stimulating Hormone, Cardio C-reactive Protein
|
0, 30, and 60 days
|
Self-reported Quality of Life
Délai: 0, 30, and 60 days
|
0, 30, and 60 days
|
|
Number of participants with adverse effects
Délai: up to 60 days
|
up to 60 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Gilbert R Kaats, PhD FACN, Integrative Health Technologies, Inc.
- Chaise d'étude: Harry G Preuss, MD MACN, Georgetown University Medical Center, Dept of Biochemistry, Medicine and Pathology
- Directeur d'études: Sidney J Stohs, PhD, Dean Emeritus, Creighton University Health Sciences Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 065
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Ad-Chol-Pre
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ComplétéCancer du poumonÉtats-Unis
-
Addpharma Inc.RecrutementHypertension EssentielleCorée, République de
-
Addpharma Inc.ComplétéHypertensionCorée, République de
-
Addpharma Inc.ComplétéHypertension EssentielleCorée, République de
-
Istanbul Demiroglu Bilim UniversityComplétéDélire | Unité de soins intensifs DélireTurquie
-
Addpharma Inc.Pas encore de recrutementHypertension EssentielleCorée, République de
-
Addpharma Inc.Pas encore de recrutementHypertension Essentielle
-
Josep M GrinyoCarlos III Health InstituteComplétéTrouble lié à la transplantation rénaleEspagne
-
Addpharma Inc.ComplétéHyperlipidémiesCorée, République de
-
University of BarcelonaLaerdal MedicalInscription sur invitationÉducation, Étudiants en soins infirmiersEspagne